The Andrea Schietinger Lab
The goal of our laboratory is to understand when, why, and how immune cells become unresponsive to tumors. We develop genetic cancer mouse models that mimic cancer development in patients, investigate T cell responses over the course of tumor development, and define the molecular and epigenetic mechanisms that are responsible for the failure to control and eliminate tumors. Detailed information about our research is available at www.schietingerlab.com.
TOX is a critical regulator of tumour-specific T cell differentiation. Scott AC, Dündar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara S, Zamarin D, Walther T, Snyder A, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman MS, Kaye J, Betel D, Philip M, Schietinger A. Nature. 2019 Jul;571(7764):270-274. doi: 10.1038/s41586-019-1324-y. Epub 2019 Jun 17.
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, Hellmann MD, Wolchok JD, Leslie CS, Schietinger A. Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.
Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, Piston DW, Pittet MJ, Lin CP, Zal T, and Schreiber H. “Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.” (2014) Oncoimmunology, 2013 Nov 1;2(11):e26677.
Andrea Schietinger, PhD
Associate Member, Immunology Program, SKI
- Cancer Immunologist Andrea Schietinger investigates immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy.
- PharmD, University of Hamburg, PhD, University of Chicago, Chicago, IL and University of Munich, Germany
- Postdoctoral Training: Fred Hutchinson Cancer Research Center and University of Washington, Seattle
- Pershing Square Sohn Award (2020)
- Cancer Research Institute Lloyd Old STAR Award (2019)
- NIH Director’s Innovator Award (2017)
- NIH/NCI K99/R00 Award (2015)
- Josie Robertson Investigator Award (2015)
- V Foundation for Cancer Research Award (2015)
- William and Ella Owens Medical Research Foundation Award (2016)
- Cancer Research Institute Irvington Fellowship (2012)
Lab News & Events
This seminar will be conducted by Zoom Webinar.
A Postdoctoral Research Position in the Immunology Program at Memorial Sloan Kettering Cancer Center, New York, is available immediately to study molecular and epigenetic mechanisms of T cell differentiation and dysfunction in the context of cancers and self-tolerance.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrea Schietinger discloses the following relationships and financial interests:
Merck & Co Inc.
Provision of Services
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.